FDA Fast-Tracks Psychedelic Therapies: A Turning Point in Mental Health Treatment

The Food and Drug Administration has granted fast-track review status to three companies studying psychedelic therapies for depression and post-traumatic stress disorder, according to reporting from The Hill. Two companies are focused on psilocybin treatments—one for treatment-resistant depression (TRD) and another for PTSD. This represents a significant departure from decades of federal drug prohibition and signals growing recognition that certain controlled substances may have legitimate medical value.

Why This Matters to Ordinary Americans

For millions of Americans struggling with depression and PTSD, current treatment options are often inadequate. An estimated 30% of people with depression do not respond to conventional antidepressants, and existing PTSD treatments fail many patients. The acceleration of psychedelic therapy research could open new pathways for people whose lives have been limited by these conditions.

This development is especially significant for veterans. 17.5 veterans die by suicide every day—a crisis that demands new solutions. Troublingly, 61% of veteran suicides involved individuals not receiving VA care, suggesting both a treatment gap and a need for more effective interventions. Psychedelic-assisted therapy shows promising results in early trials and could become a tool to address this epidemic if approved and made accessible through the VA system.

Beyond direct patient impact, this shift reflects a broader reassessment of America's $1 trillion investment in the War on Drugs—an approach that has left drug use rates unchanged while devastating communities through mass incarceration and criminalization.

Connection to Common Good Party Policy

Drug Policy Reform

The Common Good Party recognizes that $1 trillion has been spent on the War on Drugs, 806,000 Americans have died from overdoses, and drug use rates remain unchanged. This track record demands a fundamental rethinking of how America addresses substance use and mental health. The FDA's willingness to consider psychedelic therapies reflects the kind of evidence-based, outcomes-focused approach the CGP advocates. Rather than prohibition for its own sake, policy should be grounded in what actually works to improve human health.

Veterans' Health and Mental Health Crisis

CGP policy recognizes that veteran suicide is a national emergency. With 17.5 veterans dying by suicide daily and 61% not in VA care, the system is failing those who served. Expanding access to promising new therapies—including psychedelic-assisted treatment—is essential to meeting veterans where they are and providing real alternatives to conventional care that hasn't worked for many. Federal policy should prioritize getting effective treatments, including novel therapies, into VA hands and veteran hands quickly.

Disability Rights and Health Equity

PTSD and treatment-resistant depression are disabilities that profoundly affect quality of life, employment, and social participation. Advancing research into therapies that could help people recover function and independence aligns with disability rights principles of expanding choice and access to effective treatment.

How Our Plan Is Different

The FDA's fast-track action is a welcome step, but it reflects piecemeal reform within the existing system. The Common Good Party advocates for a comprehensive reimagining of drug policy and mental health treatment that goes further:

• Beyond individual drug approvals: Rather than debate one psychedelic compound at a time, CGP policy would establish a framework for evidence-based research into all compounds with therapeutic potential, removing unnecessary bureaucratic barriers that slow progress.
• Integrated veteran care: CGP policy prioritizes ensuring that all promising mental health treatments—including psychedelic-assisted therapy—are available to veterans as part of expanded, accessible VA care. This includes funding for training, research, and equitable access regardless of wealth or geography.
• Ending the War on Drugs framework: While FDA approvals treat psychedelics as medications (appropriate), CGP drug policy addresses the broader question: How do we move from criminalization toward health, harm reduction, and treatment? This includes decriminalization and deprioritization of enforcement for possession of small quantities, redirecting resources to prevention and evidence-based treatment.
• Addressing root causes: CGP recognizes that mental health crises are often linked to economic instability, lack of community, and social disconnection. Medication and therapy are essential, but so are policies addressing living wages, housing stability, and community investment.

Fact-Check